Company Shares of Great Basin Scientific (NASDAQ:GBSN) Drops by -19.26%

Great Basin Scientific (NASDAQ:GBSN) : During the past 4 weeks, traders have been relatively bearish on Great Basin Scientific (NASDAQ:GBSN), hence the stock is down -26.47% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -20.28% relative to the S&P 500. The 4-week change in the price of the stock is -25.29% and the stock has fallen -19.26% in the past 1 week.

The company shares have dropped -99.98% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $6,384.00 and the one year low was seen on Jul 8, 2016. The 50-Day Moving Average price is $1.83 and the 200 Day Moving Average price is recorded at $7.28.

The stock has recorded a 20-day Moving Average of 25.01% and the 50-Day Moving Average is 38.44%.


Great Basin Scientific (NASDAQ:GBSN): On Fridays trading session , Opening price of the stock was $1.43 with an intraday high of $1.43. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $1.27. However, the stock managed to close at $1.3, a loss of 9.09% for the day. On the previous day, the stock had closed at $1.43. The total traded volume of the day was 1,851,140 shares.

In an insider trading activity, Spafford David, director of Great Basin Scientific, Inc., executed a transaction worth $9,798 on August 21, 2015. A total of 6,665 shares were purchased at an average price of $1.47. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Great Basin Scientific, Inc. is a molecular diagnostic testing company. The Company is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious disease. The Company has a commercially available test, a diagnostic test for clostridium difficile (C. diff), which received clearance from the Food and Drug Administration (FDA). The Companys products under development also include a diagnostic test for Group B Strep., Staphylococcus Identification and Resistance Blood Infection Panel (Staph ID/R panel), STEC Test, Staph aureus (SA) Pre-Surgical Nasal Screen Test, Food Borne Pathogens Panel and Candida Blood Infection Panel. The Companys platform is an automated molecular diagnostic system, consisting of an analyzer and associated diagnostic tests.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.